[go: up one dir, main page]

AU2001271257A1 - Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy - Google Patents

Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy

Info

Publication number
AU2001271257A1
AU2001271257A1 AU2001271257A AU7125701A AU2001271257A1 AU 2001271257 A1 AU2001271257 A1 AU 2001271257A1 AU 2001271257 A AU2001271257 A AU 2001271257A AU 7125701 A AU7125701 A AU 7125701A AU 2001271257 A1 AU2001271257 A1 AU 2001271257A1
Authority
AU
Australia
Prior art keywords
inhibitor
enhance
protein kinase
radiation therapy
chemotherapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271257A
Inventor
Beverly Ann Teicher
Douglas Kirk Ways
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001271257A1 publication Critical patent/AU2001271257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001271257A 2000-06-29 2001-06-25 Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy Abandoned AU2001271257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21504300P 2000-06-29 2000-06-29
US60/215,043 2000-06-29
PCT/US2001/016490 WO2002002094A2 (en) 2000-06-29 2001-06-25 Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy

Publications (1)

Publication Number Publication Date
AU2001271257A1 true AU2001271257A1 (en) 2002-01-14

Family

ID=22801397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271257A Abandoned AU2001271257A1 (en) 2000-06-29 2001-06-25 Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy

Country Status (2)

Country Link
AU (1) AU2001271257A1 (en)
WO (1) WO2002002094A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271261A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827974A1 (en) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh COMBINATION PREPARATIONS OF PROTEINKINASE-C INHIBITORS WITH LIPIDS, LIPID ANALOGS, CYTOSTATICA OR INHIBITORS OF PHOSPHOLIPASES
ATE456367T1 (en) * 1993-12-23 2010-02-15 Lilly Co Eli PROTEIN KINASE C INHIBITORS
AU1189201A (en) * 1999-10-22 2001-05-08 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors

Also Published As

Publication number Publication date
WO2002002094A2 (en) 2002-01-10
WO2002002094A3 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
AU3000297A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU3021001A (en) Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
AU2002346504A8 (en) Therapeutic protein and treatments
PL368458A1 (en) Improved use of antitumoral compound in cancer therapy
AU2001269314A1 (en) Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
AU2001258381A1 (en) Use of parp inhibitors in cosmetic preparations
GB0105613D0 (en) Pharmaceutically effective compounds and their use
GB0119025D0 (en) Compounds and their therapeutic use
AU2001271257A1 (en) Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
HUP0303612A3 (en) Bicyclic guanidine derivatives and their therapeutic use
GB0018887D0 (en) Compound and their therapeutic use
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU2002351798A1 (en) Methods and dosage forms for improving the bioavailability of therapeutic agents
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours
IL153485A0 (en) New bispidine compounds and their use in the treatment of cardiac arrhythmias
AU2002350344A1 (en) Individualization of therapy with antihistamines
AU2001271261A1 (en) Therapeutic treatment of cancer with a protein kinase c inhibitor
GB2376943B (en) Compounds and their therapeutic use
AU6106801A (en) Trans-clitoral administration of therapy
HK1019854A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
GB0017625D0 (en) Use of compounds in therapy
GB0030058D0 (en) Use of compounds in therapy